Form 6-K BioLineRx Ltd. For: Aug 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Roth Capital Positive on BioLineRx (BLRX) Following BL-8040 Phase 2b Initiation
August 17, 2015 9:48 AM EDTRoth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target after the company announced the initiation of a Phase 2b trial for BL-8040 as a novel consolidation treatment for acute myeloid leukemia (AML).
Analyst Joseph Pantginis noted, This study is an important first step in the development of BL-8040 and the planned broadening of its profile, in our belief. The rationale for this study comes from... More
